Sickle cell disease can result in a range of acute and chronic outcomes, some of which have the potential to be life-threatening. A vaso-occlusive crisis occurs when sickle-shaped red blood cells block capillaries, leading to reduced blood flow to an organ. This causes ischemia, discomfort, and often organ damage. The prescription drugs now on the market include Hydroxyurea (sold under the brand names Droxia, Hydrea, and Siklos) and L-glutamine oral powder (marketed as Endari). However, it is important to note that these medications might cause significant negative effects. As a substitute, curcumin nanoparticles are developed and investigated for their ability to prevent sickling. The herbal plant material was obtained from the authorized vendor, then dried and finely ground. The produced coarse powder was subjected to a 24-hour extraction process, and the resulting extract was condensed and described. The docking studies were conducted for the elements of the extract. The active components were separated from the extract using column chromatography. The extract was transformed into Nano-particles and analyzed. Various compositions of F1-F5 were produced. The evaluation of the extract's ability to prevent sickling, as well as the determination of the most effective formulation, was conducted, yielding satisfactory results. The formulations were developed and analyzed using SEM (Scanning Electron Microscopy) to examine their structure. Additionally, the Drug Encapsulation Efficiency, Percent yield, and In-vitro release experiments were conducted to assess their performance.